系统性硬化症（SSc）是一种严重危及生命的组织疾病。其死亡率的一个重要方面是由合并症引起的。我们的研究旨在查明这些合并症的患病率及其与死亡率的关系，从而创建一个“合并症组”。在我们的回顾性、单中心观察性研究中，我们记录了每位患者的数据，包括人口统计信息、生命统计数据和 SSc 相关数据器官受累，以及是否存在 14 种预先确定的合并症。我们还记录了他们初次和最近一次访问的日期。为了构建生存曲线，我们使用了 Kaplan-Meier 方法，然后使用 Cox 回归模型进行多变量分析。我们的研究涉及 400 名参与者，其中 74 人不幸去世。值得注意的是，三种特定的合并症与死亡率显着相关：肿瘤、心血管疾病和多药治疗，以及两种 SSc 特异性器官受累（肺和心脏）。我们的研究成功创建了 SSc 合并症组。合并症是 SSc 患者最关心的问题，特别是心血管疾病和肿瘤。我们的研究强调了多种药物的作用。由此产生的共病组为这个复杂问题提供了全面的分析视角，并强调了数据的相互关联性。然而，我们的研究受到样本量较小的限制。因此，为了证实我们的发现，有必要进行更大规模的验证。这可能有助于创建未来的死亡率评分工具。© 作者（或其雇主）2024。根据 CC BY-NC 允许重复使用。禁止商业再利用。请参阅权利和权限。英国医学杂志出版。

Systemic sclerosis (SSc) is a serious life-threatening tissue disease. A significant aspect of its mortality arises from comorbid conditions. Our study aimed at mapping out the prevalence of these comorbidities and their relation to mortality, thus creating a 'comorbidome'.In our retrospective, single-centre observational study, we recorded each patient's data, including demographic informations, vital stats and SSc-related organ involvement, along with the presence or absence of 14 predefined comorbidities. We also documented the dates of their initial and most recent visits. To construct survival curves, we used the Kaplan-Meier method, followed by a Cox regression model for multivariate analysis.Our study involved 400 participants, 74 of whom unfortunately passed away. It is important to note that three specific comorbidities showed significant correlation to mortality: neoplasia, cardiovascular diseases and polypharmacy, as well as two SSc-specific organ involvements (lung and cardiac).Our research led to the successful creation of the SSc comorbidome. Comorbidities are a major concern for patients suffering from SSc, particularly cardiovascular diseases and neoplasms. Our study highlights the effects of polypharmacy. The resultant comorbidome offers a comprehensive and analytical perspective on this complex issue and underscores the inter-relatedness of the data. Our study, however, was limited by a small sample size. Therefore, to confirm our findings, validation on a larger scale is necessary. This could potentially contribute to the creation of a future mortality scoring tool.© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.